Amyloid immunotherapy aims to stimulate the immune system to clear amyloid-beta (Aβ) plaques from the brain. Amyloid vaccines represent a disease-modifying approach targeting the fundamental pathology of Alzheimer's disease[1]. This therapeutic strategy has evolved significantly over the past two decades, with multiple active vaccines and monoclonal antibodies in development and clinical use.
| Property | Value |
|---|---|
| Category | Immunotherapy / Disease-Modifying |
| Target | Amyloid-beta plaques and oligomers |
| Diseases | Alzheimer's Disease, Cerebral Amyloid Angiopathy |
| Delivery | Subcutaneous/intramuscular injection (active); intravenous infusion (passive) |
| Stage | FDA approved (Lecanemab, Donanemab, Aducanumab); Clinical trials (others) |
Amyloid vaccines work by stimulating antibody production against Aβ[1:1]. The therapeutic approach leverages the immune system to target and clear the pathological amyloid deposits that accumulate in the brains of Alzheimer's disease patients.
Active immunization involves administering the Aβ antigen itself, along with an adjuvant to stimulate the immune system:
Advantages:
Challenges:
Passive immunization involves administering pre-generated monoclonal antibodies directly:
Approved Antibodies:
ARIA is the primary safety concern with amyloid immunotherapy:
ARIA-E (Edema):
ARIA-H (Hemorrhage):
| Vaccine | Developer | Epitope | Phase | Status | Key Findings |
|---|---|---|---|---|---|
| ACI-35.40 | AC Immune/Janssen | Phospho-Ser396 tau | III | Recruiting | Lipidated tau antigen |
| ABvac40 | Araclón Biotech | Aβ40 C-terminus | II | Completed | Positive trends in cognition |
| CAD106 | Novartis/Cytos | Aβ1-6 | II | Completed | Antibody response achieved |
| ACC-001 | Janssen | Aβ1-7 | II | Terminated | Autoimmune concerns |
| UB-311 | United Neuroscience | Aβ1-14 | II | Ongoing | Strong antibody response |
| ACI-24 | AC Immune | Aβ1-15 | I/II | Ongoing | Oligomer-selective |
| Antibody | Developer | Target | Phase | Status | Clinical Outcome |
|---|---|---|---|---|---|
| Lecanemab | Eisai/Biogen | Aβ protofibrils | III | FDA Approved 2023 | 27% slowing of decline |
| Donanemab | Eli Lilly | N3pG Aβ | III | FDA Approved 2024 | 35% slowing of decline |
| Aducanumab | Biogen | Aβ plaques | III | Approved 2021/Withdrawn 2024 | Controversial, plaque reduction |
| Gantenerumab | Roche | Aβ plaques | III | Failed | Insufficient efficacy |
| Crenezumab | Genentech/Roche | Aβ oligomers | III | Failed | No significant benefit |
| Solanezumab | Eli Lilly | Aβ mid-domain | III | Failed | No significant benefit |
Amyloid Confirmation:
Disease Stage:
Tau Status:
| Biomarker | Utility |
|---|---|
| ApoE4 status | Predicts ARIA risk, treatment response |
| Baseline amyloid burden | Extent of plaque removal |
| Tau PET | Disease progression marker |
| Neurofilament light chain (NfL) | Treatment response |
Amyloid-targeting therapies may be combined with:
The study of Amyloid Immunotherapy Vaccines For Alzheimer'S Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in Early Alzheimer's Disease. New England Journal of Medicine. 2023;388(1):9-21. ↩︎ ↩︎ ↩︎
Sims JR, Zimmer JA, Evans CD, et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023;330(6):512-527. ↩︎
Budd Haeberlein S, Aisen PS, Barkhof F, et al. Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease. Journal of Prevention of Alzheimer's Disease. 2022;9(2):197-210. ↩︎
Mintun MA, Lo AC, Duggan Evans C, et al. Donanemab in Early Alzheimer's Disease. New England Journal of Medicine. 2021;384(18):1691-1704. ↩︎